Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)

Gastrointestinal Stromal Tumor

Completed

2

Start Date 03/01/2011

Age of Trial (yrs) 13.2

Gleevec-resistant

KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)

Block KIT + Block blood vessel growth

Specifically GIST and only GIST

PAZOGIST

Centre Leon Berard

Anne LEFRANC +33 478 78 59 46 lefranc@lyon.fnclcc.fr

Randomized

Oral

The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib. This is a phase II, randomized, multicentre study.

Patients must have progressed or have been intolerant (Grade 3) on both imatinib and sunitinib. Patients must also have an affiliation with an insurance company.

Patients will be randomly assigned to one of two groups. The first group will receive Pazopanib. The second group will receive no intervention, only best supportive care. Patients progressing in the second group may possibly receive compassionate treatment by Pazopanib.